← Back to Search

One: Patient population with hepatic lesion(s) for Liver Disease

Phase 4

Waitlist Available

Led By Jordan K Swennson, MD

Research Sponsored by Indiana University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up two years

Awards & highlights

Study Summary

This trial compares the effectiveness of two imaging methods in distinguishing between two types of liver lesions.

Eligible Conditions

Liver Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ two years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~two years

This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

new method diagnosing hepatic lesions

Trial Design

1Treatment groups

Experimental Treatment

Group I: One: Patient population with hepatic lesion(s)Experimental Treatment1 Intervention

Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

1,2-Distearoyllecithin

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor

980 Previous Clinical Trials

983,114 Total Patients Enrolled

Jordan K Swennson, MDPrincipal InvestigatorIndiana University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this procedure ascertained to be secure for patient utilization?

"Taking into account that this is a Phase 4 trial, indicating the treatment has already been approved, our team at Power rated its safety as 3 out of possible 3."

Answered by AI

Is this trial the inaugural of its kind?

"Currently, there are 14 live experiments involving this therapeutic approach in 10 cities across 3 nations. The first trial took place under the auspices of Bracco Diagnostics, Inc and was conducted in 2017 with 125 individuals which subsequently completed its Phase 1 drug approval stage. Since then, an additional 22 studies have been accomplished."

Answered by AI

What is the upper threshold of participants currently engaged in this investigation?

"Affirmative. Clinicaltrials.gov's information suggests that this medical trial, which was originally posted on February 25th 2019, is presently searching for participants. 40 volunteers are needed to partake in the study at a single clinical site."

Answered by AI

Is enrollment for this experiment still ongoing?

"Affirmative. According to the clinicaltrials.gov database, this experiment is still recruiting participants after initially being posted on February 25th 2019 and last updated August 1st 2022. A total of 40 individuals must be sourced from a single medical site for participation in the trial."

Answered by AI

Could you please detail any other research that has investigated this therapeutic approach?

"As of the present moment, 14 medical trials are in progress for this treatment with 2 of them having reached Phase 3. Most studies are taking place in Philadelphia, Pennsylvania; however, 18 locations across the nation have research facilities conducting these tests."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Jordan K. Swensson 2019. "Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03652636.